Know Cancer

or
forgot password

Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer


Phase 2
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer


Inclusion Criteria:



Must ER &/or PR+;

- Postmenopausal;

- No chemotherapy for metastatic

- No prior Exemestane or Fulvestrant

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the time to progression in women with hormone responsive advanced breast cancer treated with combination of exemestane and fulvestrant.

Outcome Time Frame:

Every 2 cycles

Safety Issue:

No

Principal Investigator

Ewa Mrozek, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University

Authority:

United States: Institutional Review Board

Study ID:

OSU-0494

NCT ID:

NCT00201864

Start Date:

September 2005

Completion Date:

Related Keywords:

  • Breast Cancer
  • Postmenopausal
  • Women
  • Breast Neoplasms

Name

Location

Ohio State UniversityColumbus, Ohio  43210